Australija - engleski - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - bupivacaine hydrochloride, quantity: 5 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 5.28 mg/ml) - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; sodium hydroxide; water for injections - indications ,bupivacaine-baxter is indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: ,surgical anaesthesia ,epidural block for surgery ,field block (minor and major nerve blocks and infiltration). ,analgesia ,continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. ,field block (minor nerve block and infiltration).

Australija - engleski - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - bupivacaine hydrochloride, quantity: 2.5 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 2.64 mg/ml) - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium chloride; sodium hydroxide - indications ,bupivacaine-baxter is indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: ,surgical anaesthesia ,epidural block for surgery ,field block (minor and major nerve blocks and infiltration). ,analgesia ,continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. ,field block (minor nerve block and infiltration).

Australija - engleski - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 156 mg (equivalent: paliperidone, qty 100 mg) - injection - excipient ingredients: dibasic sodium phosphate; water for injections; macrogol 4000; monobasic sodium phosphate monohydrate; polysorbate 20; citric acid monohydrate; sodium hydroxide - invega sustenna is indicated for the acute and maintenance treatment of schizophrenia in adults.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 117 mg (equivalent: paliperidone, qty 75 mg) - injection - excipient ingredients: sodium hydroxide; polysorbate 20; macrogol 4000; water for injections; dibasic sodium phosphate; monobasic sodium phosphate monohydrate; citric acid monohydrate - invega sustenna is indicated for the acute and maintenance treatment of schizophrenia in adults.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 39 mg (equivalent: paliperidone, qty 25 mg) - injection - excipient ingredients: dibasic sodium phosphate; sodium hydroxide; monobasic sodium phosphate monohydrate; citric acid monohydrate; polysorbate 20; water for injections; macrogol 4000 - invega sustenna is indicated for the acute and maintenance treatment of schizophrenia in adults.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 234 mg (equivalent: paliperidone, qty 150 mg) - injection - excipient ingredients: monobasic sodium phosphate monohydrate; citric acid monohydrate; water for injections; polysorbate 20; macrogol 4000; dibasic sodium phosphate; sodium hydroxide - invega sustenna is indicated for the acute and maintenance treatment of schizophrenia in adults.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 78 mg (equivalent: paliperidone, qty 50 mg) - injection - excipient ingredients: macrogol 4000; polysorbate 20; water for injections; citric acid monohydrate; dibasic sodium phosphate; sodium hydroxide; monobasic sodium phosphate monohydrate - invega sustenna is indicated for the acute and maintenance treatment of schizophrenia in adults.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epoetin lambda, quantity: 5000 iu - injection, solution - excipient ingredients: sodium hydroxide; dilute hydrochloric acid; water for injections; monobasic sodium phosphate dihydrate; polysorbate 80; sodium chloride; glycine; dibasic sodium phosphate dihydrate - treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions.. treatment of anaemia in patients with nonmyeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate. adult patients with mild to moderate anaemia (haemoglobin > 100 to less than or equal to 130g/l) scheduled for elective surgery with an expected moderate blood loss (two to four units or 900 to 1,800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery.. augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to predeposit their complete perioperative blood needs.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epoetin lambda, quantity: 3000 iu - injection, solution - excipient ingredients: polysorbate 80; monobasic sodium phosphate dihydrate; water for injections; glycine; dilute hydrochloric acid; sodium chloride; sodium hydroxide; dibasic sodium phosphate dihydrate - treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions.. treatment of anaemia in patients with nonmyeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate. adult patients with mild to moderate anaemia (haemoglobin > 100 to less than or equal to 130g/l) scheduled for elective surgery with an expected moderate blood loss (two to four units or 900 to 1,800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery.. augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to predeposit their complete perioperative blood needs.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epoetin lambda, quantity: 1000 iu - injection, solution - excipient ingredients: sodium hydroxide; water for injections; dibasic sodium phosphate dihydrate; polysorbate 80; dilute hydrochloric acid; monobasic sodium phosphate dihydrate; glycine; sodium chloride - treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions.. treatment of anaemia in patients with nonmyeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate. adult patients with mild to moderate anaemia (haemoglobin > 100 to less than or equal to 130g/l) scheduled for elective surgery with an expected moderate blood loss (two to four units or 900 to 1,800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery.. augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to predeposit their complete perioperative blood needs.